Syndax Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $45,871 | $37,958 | $20,042 | $7,680 |
Gross Profit | 39,493 | 36,679 | 19,157 | 7,680 |
EBITDA | -57,700 | -63,989 | -83,757 | -89,363 |
EBIT | -57,701 | -92,895 | -96,365 | |
Net Income | -60,715 | -71,847 | -84,846 | -94,169 |
Net Change In Cash | 45,871 | 37,958 | 20,042 | 7,680 |
Free Cash Flow | -70,666 | -87,795 | -95,162 | -57,388 |
Cash | 116,808 | 108,636 | 153,993 | 154,083 |
Basic Shares | 86,620 | 86,337 | 85,622 | 85,791 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $23,680 | $0 | $126,576 | $139,709 |
Gross Profit | 22,854 | -12 | -454 | 139,709 |
EBITDA | -313,821 | -209,140 | -151,724 | 26,263 |
EBIT | -313,829 | -209,152 | -151,757 | 26,220 |
Net Income | -318,758 | -209,360 | -143,749 | 24,926 |
Net Change In Cash | 23,680 | 0 | 126,576 | 139,709 |
Cost of Revenue | 106,722 | |||
Free Cash Flow | -274,903 | -160,601 | -133,900 | 29,002 |
Cash | 154,083 | 295,394 | 74,356 | 221,965 |
Basic Shares | 85,622 | 70,370 | 60,760 | 52,064 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$0.70 |
2025-06-30 | -$0.83 |
2025-03-31 | -$0.98 |
